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Asthma is a clinically and socioeconomically significant disease driven by inflammation. Corticosteroids 
are the mainstay of anti-inflammatory therapy in respiratory disease and although they have proven 
clinical efficacy in asthma, many asthmatic inflammatory conditions (e.g. infection, exacerbation) are 
not responsive to them. Corticosteroid insensitivity can range from relative corticosteroid insensitivity 
to steroid resistance, as seen in severe asthma (reviewed in1,2). Thus, alternative anti-inflammatory strat-
egies are urgently needed and enhancing the function of endogenous phosphatases, especially protein 
phosphatase 2A (PP2A), offer great promise.
PP2A is a master controller of multiple inflammatory signaling pathways. PP2A is a ubiquitously 
expressed serine/threonine phosphatase that exists as a tri-molecular complex of a catalytic subunit (C), 
a structural subunit (A), and a variable regulatory subunit (B) of which there are at least 3 different 
families (B55, B56, B”) each with several isoforms3. PP2A has generated much excitement as a target for 
anti-cancer therapy (reviewed in4} and has more recently emerged as a druggable target in respiratory 
disease5,6. But in order to accelerate the development of PP2A activators as a future pharmacotherapeutic 
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strategy in respiratory medicine, it is essential that we gain an advanced understanding of the regulation 
and function of PP2A in cellular models of asthmatic inflammation in vitro.
PP2A dephosphorylates a number of kinases that drive inflammatory cell signaling7,8. Notably, PP2A 
can dephosphorylate members of the mitogen-activated protein kinase (MAPK) superfamily, including 
p38 MAPK8. By regulating MAPKs, PP2A exerts significant control over cytokine regulatory networks; 
although the molecular mechanisms responsible remain relatively unexplored in airway inflammation.
We address this herein by utilizing the human alveolar epithelial cell line (A549); a transformed cell line 
widely used to examine cytokine expression in the context of asthmatic inflammation9–11. Confirmatory 
experiments were also performed with the human bronchial epithelial cell line (BEAS-2B)5,9,12. PP2A is 
a ubiquitously expressed phosphatase and our study shows that under unstimulated conditions there is 
a high level of PP2A enzymatic activity. This basal PP2A activity serves to restrain downstream effec-
tors regulated by MAPKs. Inhibition of PP2A releases restraint and thereby increases MAPK-mediated 
pro-inflammatory cytokines, including interleukin 6 and 8 (IL-6 and IL-8), as well as disable the 
anti-inflammatory function of tristetraprolin (TTP), a destabilizing RNA binding protein regulated at 
multiple levels by p38 MAPK.
Methods
Chemicals. Okadaic acid (OA) was purchased from Enzo Life Sciences (Farmingdale, NY). FTY720 
was purchased from Cayman Chemical Company (Ann Arbor, MI) and AAL(s) was synthesized5,6,13. 
Tumor necrosis factor α (TNFα ) is from R&D Systems (Minneapolis, MN). Unless otherwise specified, 
all chemicals used in this study were purchased from Sigma-Aldrich (St. Louis, MO).
Cell  culture.  The human alveolar epithelial cell line (A549) and human bronchial epithelial cell 
line (BEAS-2B) were cultured in Ham’s F-12K (Kaighn’s) Medium (Invitrogen, Carlsbad, CA) supple-
mented with penicillin (100 U/ml), streptomycin (100 μ g/ml), and fetal calf serum (10%), in accordance 
with culture conditions reported by Cornell et al.9. All experiments were performed after an overnight 
serum-starvation period (14-16 h) in Ham’s F-12K supplemented with sterile BSA (0.1%). A minimum 
of three experimental replicates performed on separate days were used for each experiment.
PP2A activity assay. PP2A activity was determined using the PP2A immunoprecipitation phos-
phatase assay kit (Merck Millipore, Darmstadt, Germany) according to the manufacturer’s instructions.
Western blotting.  Western blotting was performed using rabbit monoclonal or polyclonal antibodies 
against phosphorylated (Thr180/Tyr182) and total p38 MAPK, phosphorylated (Thr202/Tyr204) and total 
ERK, phosphorylated (Thr183/Tyr185) and total JNK (all from Cell Signaling Technology, Danvers, MA). 
The catalytic subunit of PP2A (PP2A-C) was detected with a mouse monoclonal antibody (IgG2bκ , clone 
1D6: Merck Millipore, Darmstadt, Germany). TTP was measured by Western blotting using rabbit anti-
sera against TTP (Sak21). Detection of α -tubulin was used as the loading control (mouse monoclonal 
IgG1, DM1A: Santa Cruz Biotechnology, Santa Cruz, CA). Primary antibodies were detected with goat 
anti-rabbit and anti-mouse HRP-conjugated secondary antibodies (Cell Signaling Technology, Danvers, 
MA) and visualized by enhanced chemiluminescence (PerkinElmer, Wellesley, MA).
Real-time RT-PCR.  Total RNA was extracted using the RNeasy Mini Kit (Qiagen Australia, Doncaster, 
VIC, Australia) and reverse transcription performed by using the RevertAid First strand cDNA Synthesis 
Kit (Fermentas Life Sciences, Hanover, MD) according to the manufacturer’s protocol. IL-6, IL-8 and 
TTP mRNA levels were measured using real-time RT-PCR on an ABI Prism 7500 (Applied Biosystems, 
Foster City, CA) with IL-6 (Hs00174131_m1), IL-8 (Hs00174103_m1) and TTP (Zfp36, Hs00185658_
m1) TaqMan gene expression assays and the eukaryotic 18S rRNA endogenous control probe (Applied 
Biosystems) subjected to the following cycle parameters: 50 °C for 2 min, 1 cycle; 95 °C for 10 min, 1 
cycle; 95 °C for 15 s, 60 °C for 1 min, 40 cycles and mRNA expression (fold increase) quantified by delta 
delta Ct calculations.
ELISAs.  IL-6 and IL-8 ELISAs were performed according to the manufacturer’s instructions (BD 
Biosciences Pharmingen, San Diego, CA).
Transient transfection. A549 cells (5 × 105 cells/well) were transfected with 1 μ g of pEGFP 
HA-PP2A-C, or empty vector control, using Lipofectamine 2000 (Invitrogen). After transfection, cells 
were cultured for 24 h in media without antibiotics, and then growth-arrested for 16 h in Ham’s F-12K 
supplemented with 0.1% BSA, supplemented with penicillin (100 U/ml), streptomycin (100 μ g/ml), 
before cells were assayed.
siRNA transfection.  A549 cells (5 × 105 cells/well) were transfected with siRNA against PP2A-C, or 
scrambled control, by reverse transfection with RNAiMAX according to the manufacturer’s protocols 
(Invitrogen, NY, USA). Specifically, for each well of 6-well plates, 800 ng of ON-Target plus Control 
Non-targeting siRNA (scrambled control) or ON-target plus SMART pool Human PPP2CA siRNA (aka 
PP2A-C: both from Dharmacon, Thermo-Fisher Scientific, Waltham, MA) was diluted in 500 μ L of 
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Opti-MEM Reduced Serum Media (Invitrogen). This was followed by the addition of 5 μ L of RNAiMAX 
reagent (Invitrogen) into each well and incubation at room temperature for 20 min. After transfection, 
cells were cultured for 24 h in media without antibiotics, and then growth-arrested for 16 h in Ham’s 
F-12K supplemented with 0.1% BSA, supplemented with penicillin (100 U/ml), streptomycin (100 μ g/
ml), before stimulation with TNFα (4 ng/ml).
Statistical  analysis.  Statistical analysis was performed using either the Student’s unpaired t test, 
one-way or two-way ANOVA followed by Bonferroni’s post-test. P values < 0.05 were sufficient to reject 
the null hypothesis for all analyses. Data are mean ± SEM of n ≥ 3 independent replicates.
Results
Temporal  regulation of basal PP2A enzymatic activity by OA. OA is a non-selective pharma-
cological inhibitor of PP2A9,14 and widely used to potently inhibit PP2A phosphatase activity9,15–17. To 
examine the temporal regulation of basal PP2A enzymatic activity by OA, A549 cells were treated with 
1 μ M OA for 15 min or 45 min, then washed and left for a further 1 h before measuring PP2A enzymatic 
activity. PP2A is a ubiquitously expressed phosphatase and, as shown in Fig. 1, the basal PP2A enzymatic 
activity in A549 cells is 863.7 ± 98.9 pmol free phosphate. This activity can be significantly repressed by 
45 min treatment with OA, while treatment for a shorter time period (i.e. 15 min) was without effect. 
These data indicate in part, the temporal regulation of basal PP2A activity by OA. Results from cells 
treated for both time points will be included throughout the study to demonstrate the link between 
repression of basal PP2A activity and effects on functional outcomes such as cell signaling and cytokine 
expression.
Inhibition of basal PP2A phosphatase activity allows unrestrained action of MAPK phosphop-
roteins. PP2A dephosphorylates a number of kinases that drive inflammatory cell signaling; thus its 
inhibition allows unrestrained action of a number of downstream effectors. MAPKs family members (p38 
MAPK, ERK and JNK) are important regulators of cytokine expression and are known to drive expres-
sion of two important cytokines implicated in asthmatic inflammation, IL-6 and IL-8 18–21. Accordingly, 
we examined the effect of OA on p38 MAPK, ERK and JNK phosphorylation by Western blotting. As 
shown in Fig. 2A, treating cells for 45 min with OA robustly increased p38 MAPK phosphorylation at 0.5 
and 1 h. ERK phosphorylation was enhanced at 30 min, and to a lesser extent at 1 h (Fig. 2B). JNK phos-
phorylation was also enhanced at 30 min under these conditions (Fig. 2C). Cells treated for the shorter 
time period of 15 min with OA did not show enhanced activity of MAPK phosphoproteins.
Treating A549  cells  with OA  for  45 min,  but  not  15 min,  significantly  increases  IL-6 mRNA 
expression and protein secretion. We then examined whether the inhibition of basal PP2A with 
OA has an effect on IL-6 mRNA expression and protein secretion. As shown in Fig. 3B, 45 min treatment 
with OA induced significant upregulation of IL-6 mRNA expression in a temporally distinct manner, 
with the peak of expression observed at 1 h (Fig.  3B: P < 0.05). This resulted in significant increase in 
Figure 1. Temporal regulation of basal PP2A enzymatic activity by OA. PP2A enzymatic activity was 
measured in A549 cells treated for 15 min or 45 min with 1 μ M OA, compared to vehicle-treated cells. Cells 
were washed and then PP2A enzymatic activity (measured as pmol free phosphate) detected at 1 h. Statistical 
analysis was performed using the Student’s unpaired t test where * denotes a significant decrease in PP2A 
activity compared to vehicle-treated cells (P < 0.05). Data are mean + SEM values from n = 3 independent 
experiments.
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IL-6 secretion observed at 8 and 24 h (Fig. 3D: P < 0.05). IL-6 production is p38 MAPK-mediated 18,20, 
thus, taken together with our earlier results, these data indicate that significant repression of basal PP2A 
activity by 45 min treatment with OA allows p38 MAPK activation and corresponding increases in p38 
MAPK-mediated cytokines such as IL-6. This PP2A-dependency of these results is confirmed by the lack 
of IL-6 mRNA expression and protein secretion in cells where basal PP2A activity was unaffected (see 
negative results in cells treated for only 15 min with OA (Fig. 3A,C)).
Treating A549  cells  with OA  for  45 min,  but  not  15 min,  significantly  increases  IL-8 mRNA 
expression and protein secretion. We then examined the effect of OA on IL-8 mRNA expression 
and protein secretion. Figure  4A reveals that 15 min treatment with OA has no effect on IL-8 mRNA 
expression but 45 min treatment significantly increased IL-8 mRNA at 1 h and 2 h time point (Fig. 4B: 
P < 0.05). Similarly, treatment with OA for 15 min did not increase IL-8 secretion above that achieved in 
cells treated with vehicle alone (Fig. 4C), while significant increases in IL-8 secretion were observed at 4, 
8, and 24 h after 45 min treatment with OA, compared to vehicle-treated cells (Fig. 4D).
Treating  human  bronchial  epithelial  cells  (BEAS-2B)  with  OA  for  45 min,  but  not  15 min, 
decreases PP2A enzymatic  activity  and  significantly  increases  IL-6  and  IL-8 mRNA expres-
sion and protein secretion. In order to confirm these findings in a second immortalized cell line, 
we utilized the human epithelial cell line BEAS-2B as they commonly used in in vitro studies examining 
airway inflammation with relevance to asthma5,9,12,22–24. We conducted a series of confirmatory experi-
ments (Fig. 5) to demonstrate that treating BEAS-2B cells with OA for 45 min, but not 15 min, decreases 
PP2A enzymatic activity (Fig. 5A) and significantly increases IL-6 mRNA expression (Fig. 5C) and IL-6 
secretion (Fig. 5E) (P < 0.05). IL-8 mRNA expression and protein secretion was also affected by 45 min 
Figure 2. Inhibition of basal PP2A phosphatase activity allows unrestrained action of MAPK 
phosphoproteins. A549 cells were treated for 15 min or 45 min with 1 μ M OA, compared to vehicle. Cells 
were washed and then lysates prepared at 0, 0.5 h, and 1 h, to compare temporal kinetics of (A) p38 MAPK, 
(B) ERK and (C) JNK phosphorylation by Western blotting (representative results (from n = 5 independent 
experiments) are shown as cropped blots and full-length blots are presented in Supplementary Figure 1A 
(p38 MAPK), 1B (ERK) and 1C (JNK)).
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treatment with OA (Fig.  5G,I, respectively: P < 0.05). These results confirm observations observed in 
A549 cells (Figs. 3 and 4).
Treating A549  cells  with OA  for  45 min,  but  not  15 min,  significantly  increases TTP mRNA 
expression and upregulation of TTP protein that  is hyperphosphorylated.  TTP is an impor-
tant anti-inflammatory protein that is a direct target of PP2A25 and can be regulated at multiple levels by 
p38 MAPK. TTP is an immediate early response gene whose expression is p38 MAPK-dependent26 and 
once expressed its protein stability is regulated post-translationally by p38 MAPK-mediated phosphoryl-
ation of two key serines10,25,26. Importantly, this latter step also controls TTP function as an RNA desta-
bilizing protein (phosphorylated – OFF; unphosphorylated – ON). Because PP2A controls TTP, we were 
interested to examine the impact of repression of PP2A activity on this TTP expression and function.
Firstly, we examined TTP mRNA expression, and as shown in Fig. 6A, 15 min treatment with OA had 
no effect on the time course of TTP mRNA expression. In contrast, 45 min treatment with OA signifi-
cantly increased TTP mRNA expression at 1 h (Fig. 6B: P < 0.05). Secondly, we measured TTP protein 
expression and phosphorylation with the rabbit antisera Sak2110,26. As shown in Fig.  6C, treating cells 
with OA for 45 min, but not for 15 min, increases TTP protein levels. Notably, we observe that the higher 
molecular weight immunoreactive bands for TTP predominate, especially at 1 h. This is consistent with 
Figure 3. Treating A549 cells with OA for 45 min, but not 15 min, significantly increases IL-6 mRNA 
expression and protein secretion. A549 cells were treated for (A, C) 15 min or (B, D) 45 min with 1 μ M 
OA, compared to vehicle. Cells were washed and then (A, B) IL-6 mRNA expression (results expressed as 
fold increase compared to vehicle-treated cells at 0 h) and (C, D) IL-6 protein secretion measured at 0, 1, 2, 
4, 8, and 24 h. Statistical analysis was performed using two-way ANOVA then Bonferroni’s post-test (where 
* denotes a significant effect compared to vehicle-treated cells (P < 0.05)). Data are mean ± SEM values from 
n = 4 independent experiments.
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earlier reports that inhibition of PP2A results in an equilibrium shift towards phosphorylated TTP, which 
is stable and builds up as a hyperphosphorylated (inactive) TTP25,27.
The PP2A activator FTY720 overcomes OA-mediated  inhibition of basal PP2A phosphatase 
activity  and  significantly  represses  IL-6  and  IL-8  mRNA  expression  and  cytokine  secre-
tion. Collectively, our data thus far implicates PP2A as a key regulator of cytokine expression via a 
MAPK/TTP-regulated network. That is, when PP2A is inhibited, cytokine secretion ensues. To demon-
strate this further, we used a PP2A activator FTY720 (2-amino-2-[2-(4-octylphenyl)ethyl]-1,3-propanediol 
hydrochloride28) to overcome the effect of the PP2A inhibitor (OA). A549 cells were pretreated with 
FTY720 before treatment for 45 min with OA, or vehicle. Firstly, we quantitated PP2A enzymatic activ-
ity and found that in FTY720-treated cells, OA is unable to inhibit PP2A activity to the same extent 
(Fig. 7A: P < 0.05). Secondly, we measured IL-6 and IL-8 mRNA expression at 1 h and protein secretion 
at 24 h under these conditions. Cells pretreated with FTY720 had less significantly IL-6 (Fig.  7B) and 
IL-8 (Fig. 7C) mRNA expression than OA-treated controls. IL-6 and IL-8 protein secretion results also 
followed this pattern, as shown in Fig. 7D,E, respectively.
Figure 4. Treating A549 cells with OA for 45 min, but not 15 min, significantly increases IL-8 mRNA 
expression and protein secretion. A549 cells were treated for (A, C) 15 min or (B, D) 45 min with 1 μ M 
OA, compared to vehicle. Cells were washed and then (A, B) IL-8 mRNA expression (results expressed as 
fold increase compared to vehicle-treated cells at 0 h) and (C, D) IL-8 protein secretion measured at 0, 1, 2, 
4, 8, and 24 h. Statistical analysis was performed using two-way ANOVA then Bonferroni’s post-test (where 
* denotes a significant effect compared to vehicle-treated cells (P < 0.05)). Data are mean ± SEM values from 
n = 4 independent experiments.
www.nature.com/scientificreports/
7Scientific RepoRts | 5:10063 | DOi: 10.1038/srep10063
Figure 5. Treating human bronchial epithelial cells (BEAS-2B) with OA for 45 min, but not 15 min, 
decreases PP2A enzymatic activity and significantly increases IL-6 and IL-8 mRNA expression and 
protein secretion. (A) PP2A enzymatic activity was measured in BEAS-2B cells treated for 15 min or 
45 min with 1 μ M OA, compared to vehicle-treated cells. Cells were washed and then PP2A enzymatic 
activity (measured as pmol free phosphate) detected at 1 h. Statistical analysis was performed using the 
Student’s unpaired t test where * denotes a significant decrease in PP2A activity compared to vehicle-treated 
cells (P < 0.05). BEAS-2B cells were treated for (B, D, F, H) 15 min or (C, E, G, I) 45 min with 1 μ M OA, 
compared to vehicle. Cells were washed and then (B, C) IL-6 and (F, G) IL-8 mRNA expression (results 
expressed as fold increase compared to vehicle-treated cells at 0 h) and (D, E) IL-6 and (H, I) IL-8 protein 
secretion measured at 0, 1, 2, 4, 8, and 24 h. Statistical analysis was performed using two-way ANOVA then 
Bonferroni’s post-test (where * denotes a significant effect compared to vehicle-treated cells (P < 0.05)). Data 
are mean ± SEM values from n = 3 independent experiments.
www.nature.com/scientificreports/
8Scientific RepoRts | 5:10063 | DOi: 10.1038/srep10063
The  PP2A  activator  devoid  of  sphingosine  1-  phosphate  agonism  -  AAL(s)  -  overcomes 
OA-mediated  inhibition of basal PP2A phosphatase activity and significantly represses  IL-6 
and  IL-8 mRNA expression and  cytokine  secretion.  Although FTY720 is a known activator of 
PP2A, it also has other targets. Most notably in the context of asthma, FTY720 can induce sphingosine 
1-phosphate (S1P) signaling and we have previously shown that S1P is elevated in allergic asthma29, 
drives development of the pro-asthmatic phenotype, and can induce IL-6 and IL-8 expression29–31 
. Although we did not observe upregulation of cytokine production with FTY720 in A549 cells, we 
still performed further experimentation with the FTY720 derivative 2-amino-4-(4-heptyloxyphenyl)-2
-methylbutanol [AAL(s)]5,6,13 because AAL(s) is devoid of S1P agonism. The data shown in Fig. 8 serve 
to confirm that these effects are specific to PP2A by demonstrating that PP2A activation with AAL(s) 
can overcome OA-mediated inhibition of basal PP2A phosphatase activity and significantly repress IL-6 
and IL-8 mRNA expression and cytokine secretion.
Overexpression of the catalytic subunit of PP2A (PP2A-C) overcomes OA-mediated inhibition 
of basal PP2A phosphatase activity and significantly represses  IL-6 and  IL-8 mRNA expres-
sion and cytokine secretion. As further substantiation of the role of PP2A in the control of cytokine 
secretion we overexpressed the catalytic subunit of PP2A (PP2A-C) and measured the impact on IL-6 
and IL-8 expression induced by OA. We first confirmed expression of PP2A-C in cells transfected with 
empty vector or PP2A-C (Fig. 9A) and then examined the impact of OA treatment (45 min) on PP2A 
phosphatase activity and cytokine expression. As shown in Fig.  9B, in cells where PP2A-C is overex-
pressed, OA is unable to inhibit PP2A activity to the same extent as controls. Further, cells transfected 
with PP2A-C plasmid significantly repressed OA-induced IL-6 and IL-8 mRNA expression (Fig. 9C,D) 
and protein secretion (Fig. 9E,F), respectively.
OA inhibits TNFα-induced PP2A phosphatase activity and increases TNFα-induced IL-6 and 
IL-8 mRNA expression and protein secretion.  Our study thus far shows the important role played 
Figure 6. Treating A549 cells with OA for 45 min, but not 15 min, significantly increases TTP mRNA 
expression and upregulation of TTP protein that is hyperphosphorylated. A549 cells were treated for 
15 min or 45 min with 1 μ M OA, compared to vehicle. Cells were washed and at the indicated times (A, 
B) TTP mRNA expression (results expressed as fold increase compared to vehicle-treated cells at 0 h) and 
(C) TTP protein upregulation was measured by Western blotting with α -tubulin as the loading control 
(representative results are shown as cropped blots and full-length blots are presented in Supplementary 
Figure 2). Please note that bands of immunoreactivity for TTP at higher molecular weight indicate 
phosphorylated forms of TTP. Statistical analysis was performed using two-way ANOVA then Bonferroni’s 
post-test (where * denotes a significant effect compared to vehicle-treated cells (P < 0.05)). Data are 
mean + SEM values from n = 4 independent experiments.
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by basal PP2A enzymatic activity in restraining cytokine expression in unstimulated cells. To mimic the 
inflammatory milieu in asthma we now examined the impact of OA (for 45 min) on IL-6 and IL-8 expres-
sion stimulated by TNFα – a pro-inflammatory cytokine implicated in asthma. As shown in Fig. 10A, 
TNFα increases PP2A activity and this can be significantly repressed by OA. We then examined the 
Figure 7. The PP2A activator FTY720 overcomes OA-mediated inhibition of basal PP2A phosphatase 
activity and significantly represses IL-6 and IL-8 mRNA expression and cytokine secretion. A549 cells 
were treated for 6 h with 2.5 μ M FTY720 prior to 45 min with 1 μ M OA, compared to vehicle. Cells were 
washed and then (A) PP2A activity measured at 1 h, (B, C) IL-6 and IL-8 mRNA expression measured at 
1 h (results expressed as fold increase compared to vehicle-treated cells) and (D, E) IL-6 and IL-8 protein 
secretion measured at 24 h. Statistical analysis was performed using one-way ANOVA then Bonferroni’s 
post-test (where * denotes a significant effect of OA or § FTY720) (P < 0.05)). Data are mean + SEM values 
from n = 3 independent experiments.
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Figure 8. The PP2A activator devoid of sphingosine 1- phosphate agonism - AAL(s) -overcomes OA-
mediated inhibition of basal PP2A phosphatase activity and significantly represses IL-6 and IL-8 mRNA 
expression and cytokine secretion. A549 cells were treated for 6 h with 2.5 μ M AAL(s) prior to 45 min 
with 1 μ M OA, compared to vehicle. Cells were washed and then (A) PP2A activity measured at 1 h, (B, C) 
IL-6 and IL-8 mRNA expression measured at 1 h (results expressed as fold increase compared to vehicle-
treated cells) and (D, E) IL-6 and IL-8 protein secretion measured at 24 h. Statistical analysis was performed 
using one-way ANOVA then Bonferroni’s post-test (where * denotes a significant effect of OA or § AAL(s) 
(P < 0.05)). Data are mean + SEM values from n = 3 independent experiments.
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Figure 9. Overexpression of the catalytic subunit of PP2A (PP2A-C) overcomes OA-mediated inhibition 
of basal PP2A phosphatase activity and significantly represses IL-6 and IL-8 mRNA expression and 
cytokine secretion. A549 cells were transfected with empty vector or plasmid expressing PP2A-C, prior 
to 45 min with 1 μ M OA, compared to vehicle. Cells were washed and then (A) PP2A-C overexpression 
confirmed by Western blotting (representative results are shown as cropped blots and full-length blots are 
presented in Supplementary Figure 3), (B) PP2A activity measured at 1 h, (C, D) IL-6 and IL-8 mRNA 
expression measured at 1 h (results expressed as fold increase compared to vehicle-treated cells) and (E, F) 
IL-6 and IL-8 protein secretion measured at 24 h. Statistical analysis was performed using one-way ANOVA 
then Bonferroni’s post-test (where * denotes a significant effect of OA or § PP2A-C) (P < 0.05)). Data are 
mean + SEM values from n = 3 independent experiments.
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Figure 10. OA inhibits TNFα-induced PP2A phosphatase activity and increases TNFα-induced IL-6 
and IL-8 mRNA expression and protein secretion. (A) PP2A enzymatic activity was measured in A549 
cells treated for 45 min with vehicle or 1 μ M OA. Cells were washed before stimulation with TNFα (4 ng/ml) 
and then PP2A enzymatic activity (measured as pmol free phosphate) was detected at 1 h. Statistical analysis 
was performed using one-way ANOVA then Bonferroni’s post-test (where § denotes a significant effect 
of OA on on TNFα -induced effects). (B-E) A549 cells were treated for 45 min with vehicle or 1 μ M OA. 
Cells were washed before stimulation with TNFα (4 ng/ml). (B) IL-6 and (C) IL-8 mRNA expression was 
measured at 0, 1, 2, 4, 8, and 24 h (results expressed as fold increase compared to vehicle-treated cells at 0 h) 
and (D) IL-6 and (E) IL-8 protein secretion measured at 24 h. Statistical analysis was performed using two-
way ANOVA then Bonferroni’s post-test (where §denotes a significant effect of OA on TNFα -induced effects 
(P < 0.05)). Data are mean ± SEM values from n = 3 independent experiments.
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Figure 11. Specific knockdown of PP2A with siRNA reduces TNFα-induced PP2A protein levels 
and activity and results in increased TNFα-induced IL-8 and IL-6 mRNA expression and protein 
secretion. A549 cells transfected with scrambled control or siRNA against PP2A-C were stimulated with 
TNFα (4 ng/ml) before: (A) PP2A-C knockdown at 1 h was confirmed by Western blotting (representative 
results are shown as cropped blots and full-length blots are presented in Supplementary Figure 4); (B) 
PP2A enzymatic activity detected at 1 h (measured as pmol free phosphate); (C) IL-6 and (D) IL-8 mRNA 
expression measured at 1 h (results expressed as % of TNFα -induced mRNA expression in scrambled control 
(designated as 100%)) ; and (E, F) IL-6 and IL-8 protein secretion measured at 24 h (results expressed as 
% of TNFα -induced protein secretion in scrambled control (designated as 100%)). Statistical analysis was 
performed using Student’s unpaired t test (where § denotes a significant effect of siRNA against PP2A-C on 
TNFα -induced effects (P < 0.05)). Data are mean ± SEM values from n = 3 independent experiments.
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time course of TNFα -induced IL-6 (Fig. 10B) and IL-8 (Fig. 10C) mRNA expression and found that OA 
treatment significantly increased TNFα -induced cytokine expression at a number of time-points and 
that this resulted in significant increase in TNFα -induced IL-6 and IL-8 secretion at 24 h (Fig.  10D,E, 
respectively: P < 0.05).
Specific  knockdown  of  PP2A  with  siRNA  reduces  TNFα-induced  PP2A  protein  levels  and 
activity and results  in  increased TNFα-induced  IL-8 and  IL-6 mRNA expression and protein 
secretion. Finally, to demonstrate that these OA-mediated effects were specific to PP2A, A549 cells 
were transfected with scrambled control or siRNA against PP2A-C before TNFα stimulation. When 
PP2A-C was knocked down (confirmed by Western blotting in Fig.  11A) we observed significant 
reduction in TNFα -induced PP2A enzymatic activity (Fig.  11B) with a corresponding upregulation of 
TNFα -induced IL-6 and IL-8 mRNA expression and protein secretion from A549 cells (Fig.  11C–F, 
respectively: P < 0.05)
Discussion
To explore the role of PP2A in cytokine expression in human lung epithelial cells, we took multiple 
approaches to modulate PP2A phosphatase activity by using a PP2A inhibitor, OA; two PP2A activators, 
FTY720 and AAL(s); an expression plasmid to overexpress the catalytic subunit of PP2A (PP2A-C); and 
siRNA to knockdown PP2A-C. These studies reveal the important role played by PP2A in cytokine reg-
ulation in the context of airway inflammation and demonstrate the link between perturbation of PP2A 
activity and effects on functional outcomes such as cell signaling and cytokine expression.
Several studies have demonstrated that PP2A serves as a negative regulator of MAPKs8,32,33 and in 
support we found that inhibition of PP2A by OA upregulates p38 MAPK, ERK and JNK phosphoryla-
tion in A549 cells. These results demonstrate that the basal activity of PP2A in untreated cells restrains 
MAPK-mediated cell signaling in A549 cells. In our previous studies we demonstrated that IL-6 and IL-8 
are two major cytokines upregulated via MAPK-mediated pathways18–21. JNK has been reported to be 
regulated by PP2A and play a role in IL-8 production in models of TNFα and lipopolysaccharide-induced 
lung inflammation, with an important consequences for severe asthma34,35.
Notably, PP2A inhibition also has a significant impact on the critical anti-inflammatory protein - TTP. 
TTP is an mRNA destabilizing protein that targets numerous cytokines36, including those involved in 
asthmatic inflammation. Its expression and function are p38 MAPK-dependent26,27. There is a dynamic 
equilibrium between unphosphorylated and phosphorylated forms of TTP. The unphosphorylated form 
of TTP is active and capable to decay cytokine mRNA. However, this form of TTP is unstable and under-
goes proteosomal degradation, whereas phosphorylated TTP is stable but unable to target cytokines 
mRNA for decay. Importantly, TTP is a direct target of PP2A; as PP2A phosphatase activity is responsi-
ble for dephosphorylation of TTP at two key serines (Ser52 and Ser178)25. In this way, PP2A shifts this 
balance of TTP towards unphosphorylated TTP via dephosphorylation25,27. Our study demonstrates that 
inhibition of PP2A (with OA for 45 min) significantly induces TTP mRNA expression but the resulting 
TTP protein has electrophoretic mobility in immunoblots indicative of hyperphosphorylated forms of 
TTP. Our study concurs with previous reports that demonstrate that inhibition of PP2A phosphatase 
activity causes accumulation of hyperphosphorylated and stable TTP protein25,37, suggesting that in the 
absence of PP2A activity, the balance is shifted towards stable, but inactive, phosphorylated forms of TTP.
Our study utilizing OA demonstrates the important anti-inflammatory control exerted by PP2A 
phosphatase basal activity in A549 lung epithelial cells. These studies were confirmed in BEAS-2B cells. 
Given that OA is a non-selective pharmacological inhibitor, we have directly implicated PP2A with 
PP2A-C overexpression as well as PP2A activators. A number of small molecules have been reported 
to activate PP2A4. To date the best known of these is the sphingosine analog FTY720 (fingolimod) and 
we have utilized it herein overcome OA-mediated repression of PP2A enzymatic activity and repress 
cytokine expression. But it is important to note that FTY720 is also an agonist/antagonist of the sphin-
gosine 1-phosphate (S1P) pathway and we and others have shown that S1P is pro-inflammatory and 
pro-asthmatic29–31,38,39. Therefore we utilized AAL(s), a PP2A activator devoid of S1P agonism5,6,13 to 
confirm the anti-inflammatory effect of basal PP2A in A549 cells.
Our study demonstrates that basal PP2A activity restrains cytokine expression in a cellular model of 
asthmatic inflammation and highlights an important role for MAPKs and TTP. Moreover, PP2A plays 
an important role in cytokine expression in cells stimulated with TNFα ; we show that inhibition of 
PP2A with OA, and more specifically with PP2A-C knockdown by siRNA, results in significant increases 
in cytokine production. Taken together our study has revealed, in part, the molecular mechanisms of 
PP2A anti-inflammatory function and highlight the potential of boosting the power of endogenous phos-
phatases as novel anti-inflammatory strategies to combat asthmatic inflammation.
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